ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

November 09, 2006 10:09 ET

ART Advanced Research Technologies Announces Financial Results Conference Call for Third Quarter 2006

MONTREAL, CANADA--(CCNMatthews - Nov. 9, 2006) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, invites you to participate in a conference call to discuss the company's financial results for the third quarter ended September 30, 2006. The conference call will follow the press release issued earlier on the same day, and will be held on:

Tuesday, November 14, 2006

8:30 a.m. (ET)

To participate in the conference call when dialing within the Montreal area, please dial (514) 861-0443, or (866) 898-9626 for the rest of North America. Outside of North America, please dial (514) 861-0443. Participants are asked to dial 10 minutes prior to the start time.

The conference call will feature Sebastien Gignac, President and Chief Executive Officer, and Jacques Bedard, Chief Financial Officer.

A replay of the conference call will be available until November 21, 2006. To listen to the replay from the Montreal area, please dial (514) 861-2272, or, (800) 408-3053 for the rest of North America. From outside of North America, please dial (514) 861-2272. The access code for the replay is 3201352#.

We look forward to your participation and thank you for your interest in ART Advanced Research Technologies Inc.

About ART

ART Advanced Research Technologies Inc. is a leader in optical molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. eXplore Optix™, an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed by GE Healthcare and is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra™ line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART Advanced Research Technologies Inc.'s regulatory filings with Canadian Securities Commissions and the Securities and Exchange Commission in the United States.

Contact Information